JP2023521754A5 - - Google Patents
Info
- Publication number
- JP2023521754A5 JP2023521754A5 JP2022561400A JP2022561400A JP2023521754A5 JP 2023521754 A5 JP2023521754 A5 JP 2023521754A5 JP 2022561400 A JP2022561400 A JP 2022561400A JP 2022561400 A JP2022561400 A JP 2022561400A JP 2023521754 A5 JP2023521754 A5 JP 2023521754A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- pharmaceutical composition
- ofatumumab
- treatment
- treatment according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025151221A JP2026009900A (ja) | 2020-04-09 | 2025-09-11 | 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20169007.0 | 2020-04-09 | ||
| EP20169007 | 2020-04-09 | ||
| EP20176057 | 2020-05-22 | ||
| EP20176057.6 | 2020-05-22 | ||
| US202063076628P | 2020-09-10 | 2020-09-10 | |
| US63/076,628 | 2020-09-10 | ||
| US202163166054P | 2021-03-25 | 2021-03-25 | |
| US63/166,054 | 2021-03-25 | ||
| PCT/EP2021/059285 WO2021204994A1 (en) | 2020-04-09 | 2021-04-09 | Ofatumumab for treating ms while maintaining serum igg |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025151221A Division JP2026009900A (ja) | 2020-04-09 | 2025-09-11 | 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023521754A JP2023521754A (ja) | 2023-05-25 |
| JP2023521754A5 true JP2023521754A5 (https=) | 2024-04-19 |
| JP7794757B2 JP7794757B2 (ja) | 2026-01-06 |
Family
ID=75362645
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022561400A Active JP7794757B2 (ja) | 2020-04-09 | 2021-04-09 | 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ |
| JP2025151221A Pending JP2026009900A (ja) | 2020-04-09 | 2025-09-11 | 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025151221A Pending JP2026009900A (ja) | 2020-04-09 | 2025-09-11 | 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230151106A1 (https=) |
| EP (3) | EP4707302A2 (https=) |
| JP (2) | JP7794757B2 (https=) |
| KR (1) | KR20220166827A (https=) |
| CN (1) | CN115427068A (https=) |
| AU (1) | AU2021253674A1 (https=) |
| BR (1) | BR112022019038A2 (https=) |
| CA (1) | CA3176574A1 (https=) |
| DE (1) | DE202021004005U1 (https=) |
| IL (1) | IL296701A (https=) |
| MX (1) | MX2022012600A (https=) |
| WO (1) | WO2021204994A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3733712T (lt) | 2016-08-15 | 2023-09-11 | Novartis Ag | Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| WO2022219057A1 (en) * | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| WO2012018704A1 (en) * | 2010-08-02 | 2012-02-09 | Sanofi-Aventis U.S. Llc | Use of teriflunomide for treating multiple sclerosis |
| EP2748198A2 (en) * | 2011-09-27 | 2014-07-02 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis |
| LT3733712T (lt) * | 2016-08-15 | 2023-09-11 | Novartis Ag | Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą |
| MX2022003010A (es) * | 2019-09-11 | 2022-06-02 | Novartis Ag | Tratamiento de la emr mediante cambio de terapia. |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| WO2022219057A1 (en) * | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
| US20240343821A1 (en) * | 2021-08-16 | 2024-10-17 | Novartis Ag | Ofatumumab for treating pediatric ms |
-
2021
- 2021-04-09 EP EP25215090.9A patent/EP4707302A2/en active Pending
- 2021-04-09 MX MX2022012600A patent/MX2022012600A/es unknown
- 2021-04-09 DE DE202021004005.6U patent/DE202021004005U1/de active Active
- 2021-04-09 AU AU2021253674A patent/AU2021253674A1/en active Pending
- 2021-04-09 WO PCT/EP2021/059285 patent/WO2021204994A1/en not_active Ceased
- 2021-04-09 JP JP2022561400A patent/JP7794757B2/ja active Active
- 2021-04-09 CN CN202180027438.7A patent/CN115427068A/zh active Pending
- 2021-04-09 US US17/995,820 patent/US20230151106A1/en active Pending
- 2021-04-09 EP EP21716231.2A patent/EP4132564A1/en active Pending
- 2021-04-09 BR BR112022019038A patent/BR112022019038A2/pt not_active Application Discontinuation
- 2021-04-09 IL IL296701A patent/IL296701A/en unknown
- 2021-04-09 CA CA3176574A patent/CA3176574A1/en active Pending
- 2021-04-09 EP EP25220406.0A patent/EP4682171A3/en active Pending
- 2021-04-09 KR KR1020227038773A patent/KR20220166827A/ko active Pending
-
2025
- 2025-09-11 JP JP2025151221A patent/JP2026009900A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sekiguchi et al. | A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia | |
| JP2023521754A5 (https=) | ||
| Nash et al. | Etanercept to control inflammation in the treatment of complicated neurocysticercosis | |
| Guarneri et al. | High‐dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open‐label clinical trial using an objective score of clinical evaluation system | |
| De Stefano et al. | Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients | |
| JP2018531936A5 (https=) | ||
| Rhoades et al. | RETRACTED: Potential role of lampalizumab for treatment of geographic atrophy | |
| Kim et al. | Adjuvant rituximab treatment for pemphigus: a retrospective study of 45 patients at a single center with long‐term follow up | |
| RU2014131265A (ru) | Способ обеспечения требуемых уровней фактора 2 роста глии в плазме | |
| Wrona | Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed? | |
| Doria et al. | Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review | |
| Shukla et al. | Novel non-biologic targets for inflammatory bowel disease | |
| Miyata et al. | Efficacy of Benralizumab and Clinical Course of Igg4 on Eosinophilic | |
| Hamaguchi et al. | Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open‐label study | |
| Giannakopoulos et al. | Should we be using upstream beta-blocker therapy for acute myocardial infarction? | |
| Johnson et al. | A retrospective study on the efficacy of total absorbed orbital doses of 12, 16 and 20 Gy combined with systemic steroid treatment in patients with Graves’ orbitopathy | |
| Spiera et al. | OP0171 phase 3 trial of lenabasum, a CB2 agonist, for the treatment of diffuse cutaneous systemic sclerosis (dcSSc) | |
| Miller et al. | The role of the renin-angiotensin system and oxidative stress in spontaneously hypertensive rat mesenteric collateral growth impairment | |
| Noda et al. | Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community‐based hospital | |
| Zeng et al. | LB0001 head-to-head comparison of TLL-018 and tofacitinib in patients with active rheumatoid arthritis: interim results from a phase IIa study | |
| Asai et al. | Clinical effectiveness of baricitinib and abatacept in patients with rheumatoid arthritis | |
| Naniwa et al. | Long‐term efficacy and safety of add‐on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors | |
| Pender et al. | Certolizumab for the treatment of localized pyoderma gangrenosum associated with Crohn's disease: A case report. | |
| CN115175678A (zh) | 使用btk抑制剂及其组合治疗dlbcl的方法 | |
| JP2019505598A5 (https=) |